Is there a biomarker for which patients benefit from tarlatamab?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?

11 Answers

How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?

164 Answers

For the neoadjuvant treatment for thymoma, when do you favor CAP with prednisone over CAP?

1 Answers

In NSCLC, would you manage other MET alterations, such as a MET T618T mutation, in the same way as a MET exon 14 skipping mutation?

1 Answers

How are you interpreting the PACIFIC post hoc findings suggesting that concomitant PPIs and antibiotic use may influence outcomes with consolidation durvalumab in patients with unresectable stage III NSCLC?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service